Summary of transactions
Okupe Oluyemi, the Chief Financial Officer of Hims & Hers Health, Inc. (NASDAQ: HIMS), sold a total of 54,927 shares of the company’s Class A common stock in two trades executed in mid-April, producing proceeds of approximately $1,457,305. The dispositions were carried out pursuant to a Rule 10b5-1 trading plan that Mr. Oluyemi adopted on May 21, 2025.
Details of the April sales
On April 16, 2026, Mr. Oluyemi sold 36,922 shares of Class A common stock at an average price of $25.8964 per share. The executed prices for that block ranged from $25.74 to $26.29 per share.
On April 17, 2026, he sold an additional 18,005 shares of Class A common stock at an average of $27.8344 per share. The prices for the April 17 transactions ranged from $27.70 to $27.97 per share.
Together, the two transactions generated approximately $1,457,305, with per-share execution prices spanning from $25.8964 to $27.8344.
Option exercise and terms
Also on April 17, 2026, Mr. Oluyemi exercised stock options to acquire 6,184 shares of Class A common stock. The exercise price was $5.01 per share, resulting in a total exercise cost of $30,981.
The options exercised carry a vesting schedule that began on January 24, 2022. Under that schedule, 25% vested on the twelve-month anniversary, with the remaining portion vesting in 36 equal monthly installments thereafter, contingent on continuous service. The options are set to expire on February 23, 2032.
Post-transaction ownership
Following these transactions, Mr. Oluyemi directly holds 270,046 shares of Hims & Hers Class A common stock. In addition, 7,853 shares are held indirectly through the Oluyemi Okupe Separate Property Trust dated 9-1-2021. He also retains 129,403 derivative shares in the form of stock options.
Context - regulatory and marketplace developments
These insider transactions coincide with several developments affecting Hims & Hers. The Food and Drug Administration is scheduled to hold discussions on July 23 and July 24 regarding the removal of restrictions on a number of injectable peptides - a regulatory matter that market participants are watching for its potential to affect companies operating in relevant therapeutic and consumer health segments.
Analyst coverage has reflected the mixed view on the company’s trajectory. Leerink Partners continues to carry a Market Perform rating with a $25 price target, characterizing the FDA discussions as a positive development for Hims & Hers. Separately, BofA Securities has adjusted its price target for the company on two occasions: it initially raised the target to $25 from $21 citing possible benefits from peptides, and later lowered it to $21 from $23 due to concerns related to future EBITDA estimates.
Competition dynamics in the weight management market also figure in the company’s operating environment. Amazon Pharmacy announced plans to offer Eli Lilly’s GLP-1 medication Foundayo with same-day delivery, a move that increases competition in channels relevant to Hims & Hers’ consumer-facing health offerings.
Takeaway
The combination of the CFO’s share sales and option exercise, ongoing regulatory deliberations over injectable peptides, shifting analyst price targets, and heightened competition in the weight management distribution channel frames a complex near-term backdrop for Hims & Hers. The facts above document the specific insider transactions and the contemporaneous external developments that market observers are tracking.